Information

Dear user, the application need JavaScript support. Please enable JavaScript in your browser.

You are browsing as a GUEST
Title of the item:

Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan

Title :
Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan
Authors :
Kao-Chi Chang
Shui-Yi Tung
Kuo-Liang Wei
Chen-Heng Shen
Yung-Yu Hsieh
Wei-Ming Chen
Yi-Hsing Chen
Chun-Hsien Chen
Chi-Wei Yen
Huang-Wei Xu
Wei-Lin Tung
Chao-Hung Hung
Sheng-Nan Lu
Te-Sheng Chang
Show more
Subject Terms :
Medicine
Science
Source :
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Publisher :
Nature Portfolio, 2021.
Publication Year :
2021
Collection :
LCC:Medicine
LCC:Science
Document Type :
article
File Description :
electronic resource
Language :
English
ISSN :
2045-2322
Relation :
https://doaj.org/toc/2045-2322
DOI :
10.1038/s41598-021-93095-x
Access URL :
https://doaj.org/article/c3f883780e4f498eae4652d3f293f1fe
Accession Number :
edsdoj.3f883780e4f498eae4652d3f293f1fe
Academic Journal
Abstract Clinical trials showed pangenotypic direct-acting antivirals’ (DAAs) excellent efficacy and safety when treating hepatitis C virus (HCV). Two pangenotypic regimens were examined, glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/velpatasvir (SOF/VEL), in a real-world Taiwanese setting, including all HCV patients treated with GLE/PIB or SOF/VEL from August 2018 to April 2020. The primary endpoint was sustained virologic response 12 weeks after treatment cessation (SVR12), including adverse events (AEs). A total of 1,356 HCV patients received pangenotypic DAA treatment during the study: 742 and 614 received GLE/PIB and SOF/VEL, respectively. The rates of SVR12 for GLE/PIB and SOF/VEL were 710/718 (98.9%) and 581/584 (99.5%), respectively, by per-protocol analysis, and 710/742 (95.7%) and 581/614 (94.6%), respectively, by evaluable population analysis. Eleven (GLE/PIB: 8, SOF/VEL: 3) did not achieve SVR12. The most common AEs for GLE/PIB and SOF/VEL were pruritus (17.4% vs. 2.9%), abdominal discomfort (5.8% vs. 4.4%), dizziness (4.2% vs. 2%), and malaise (3.1% vs. 2.9%). Laboratory abnormalities were uncommon; only
Please log in to access the full text.

We use cookies to help identify your computer so we can tailor your user experience, track shopping basket contents and remember where you are in the order process.